#USA #New York #Class Action #Levi Korsinsky #Regencell Bioscience

Levi & Korsinsky's Alert to Regencell Investors

Levi & Korsinsky, LLP has announced an important reminder to current and past investors of Regencell Bioscience Holdings Limited (NASDAQ: RGC). An impending securities class action lawsuit has been filed, aimed at recovering potential losses incurred by investors who purchased Regencell securities between October 28, 2024 and October 31, 2025. The deadline to apply for lead plaintiff status in this case is set for June 23, 2026.

Background on the Class Action

The class action lawsuit arises from significant financial concerns regarding the company's valuation and operational shortcomings. Reports indicate that Regencell has a striking gap between its operational expenditure on research and the colossal market valuation it commanded. Specifically, it is troubling that while Regencell reported a research and development budget of approximately $0.95 million for the fiscal year ending June 30, 2025, the average cost to bring a new drug to market reportedly exceeds $4 billion, a gap that has raised eyebrows.

On November 3, 2025, the company’s stock plummeted by 18.56% following the announcement of a U.S. Department of Justice subpoena and ongoing investigation into its stock trading practices. This decline underlines concerns raised in the lawsuit about the company's financial disclosures.

The Financial Disparity

During the class period, Regencell did not generate any revenue and had no approved products for sale. Compounding this issue, the company managed to surge its share price from less than $0.30 to a high of $78.00 per share in June 2025, marking an astonishing increase of 48,650%. These figures not only seem disconnected from its operational realities but also position Regencell as having one of the highest market valuations relative to its peers within the NASDAQ Biotechnology Index.

For instance, the company operated with a skeletal workforce of just twelve employees while pursuing treatments for conditions considered difficult to treat, like ADHD and ASD. This raises critical questions about investor expectations based on the company’s scant operational scale relative to its alleged potential.

Steps for Investors

Levi & Korsinsky invites affected investors to evaluate their eligibility for compensation, emphasizing that no upfront fees are required to join the class action. Investors who purchased shares during the specified class period and suffered losses stand a chance to recover part of their investments.

To participate, individuals are encouraged to collect their brokerage records detailing purchase dates and quantities of shares. Investors can contact Joseph E. Levi, Esq., for a no-obligation evaluation. Potential plaintiffs need to be aware that they do not have to appear in court to benefit from the lawsuit; submitting a claim form is sufficient.

FAQs on RGC Lawsuit

The firm has compiled FAQs to assist potential participants:
1. Who is eligible? Investors who purchased RGC stock between the specified dates and experienced losses may qualify.
2. What was the stock's decline? After the DOJ investigation's disclosure, shares fell approximately $3.09 per share.
3. What actions should be taken? Gather pertinent brokerage records and reach out to Levi & Korsinsky for guidance.
4. Is participation costly? No. The process operates on a contingency basis, meaning no upfront payments are needed.

Conclusion

In light of these developments, Levi & Korsinsky emphasizes the importance of swift action by investors affected by this situation. As the deadline for lead plaintiff status approaches, those who have faced financial setbacks related to Regencell's trading practices are urged to seek legal counsel to explore their options before June 23, 2026. The efforts of Levi & Korsinsky reflect their commitment to representing shareholders nationwide, aiming to hold companies accountable for transparent disclosures and fair valuations.